AngioDynamics, Inc. filings document regulatory disclosures for a Nasdaq-listed medical technology company focused on vascular disease, thrombectomy, oncology and surgical device markets. Recent Form 8-K reports furnish quarterly and annual financial results, Regulation FD investor presentation materials, and forward-looking statement language tied to product strategy, competitive position, cash flows and operating plans.
The filing record also covers governance and material-event disclosures, including annual meeting voting results, director elections, auditor ratification, advisory executive-compensation votes, executive transition and retirement arrangements, and patent-enforcement litigation involving the company’s thrombectomy intellectual property and self-expanding funnel technology. Proxy materials provide compensation tables, board matters and shareholder-vote mechanics.
Trowbridge Stephen A reported acquisition or exercise transactions in this Form 4 filing.
AngioDynamics EVP and CFO Stephen A. Trowbridge received equity awards on July 15, 2026. He was granted 53,257 restricted stock units, vesting in four equal annual installments each July 15 from 2027 through 2030, and 53,257 performance rights, each a contingent right to one share of common stock. Payout on the performance rights can range from 0% up to 240% of the target, based on relative total shareholder return over a three-year performance period. After the restricted stock unit award, his directly held common stock reported in this line totals 297,819 shares.
Piccinini Laura reported acquisition or exercise transactions in this Form 4 filing.
AngioDynamics Inc. senior vice president of international operations Laura Piccinini received equity awards on July 15, 2026. She was granted 19,860 restricted stock units, each representing a contingent right to one common share, vesting in four equal annual installments from July 15, 2027 through July 15, 2030, bringing her direct common stock holdings to 78,388 shares. She also received 19,860 performance rights, each tied to one share of common stock, with between 0% and 200% of the target amount earned over a three-year period and a potential 20% adjustment, for a maximum payout of up to 240% of the target based on total shareholder return relative to a peer group.
Nighan Warren JR reported acquisition or exercise transactions in this Form 4 filing.
AngioDynamics Inc. reported that SVP Quality and Regulatory Warren Nighan Jr. received equity awards on July 15, 2026. He was granted 17,966 restricted stock units, vesting in four equal annual installments from July 15, 2027 through 2030, and 17,966 performance rights tied to three-year relative total shareholder return. Following the RSU grant, he directly holds 84,092 shares of common stock.
AngioDynamics Inc. reported that officer Chad Thomas Campbell, SVP/GM Vascular Access, received equity awards on July 15, 2026. He acquired 16,081 restricted stock units, each convertible into one share of common stock, vesting in four equal annual installments on July 15 of 2027, 2028, 2029 and 2030. He also received 16,081 performance rights, each representing a contingent right to one share, with 0–200% of the target (plus a possible 20% adjustment, for up to 240% of target) earned based on three-year total shareholder return relative to a peer group. Following these grants, he directly held 104,540 shares of common stock.
Weiss Lawrence T reported acquisition or exercise transactions in this Form 4 filing.
AngioDynamics SVP and Chief Legal Officer Lawrence T. Weiss received equity-based compensation on July 15, 2026. He was granted 21,288 restricted stock units, each representing a contingent right to one share of common stock, plus 21,288 performance rights, also initially tied one-for-one to common shares.
The restricted stock units vest in four equal annual installments on July 15 of 2027, 2028, 2029 and 2030. The performance rights are earned over a three-year performance period based on total shareholder return versus a peer group, with a potential payout from 0% up to 240% of the 21,288-share target; any unearned awards are forfeited. Following these grants, Weiss directly holds 112,618 shares of common stock.
AngioDynamics Inc. executive Lawrence T. Weiss, SVP and Chief Legal Officer, reported an exempt disposition of 2,267 shares of common stock on July 16, 2026. The shares were withheld at $14.14 per share to satisfy tax obligations from vesting restricted stock units granted July 16, 2025, leaving 91,330 shares held directly.
AngioDynamics EVP and CFO Stephen A. Trowbridge reported tax-related share withholdings tied to restricted stock unit vesting. On July 16, 17 and 20, 2026, a total of 12,067 common shares were disposed of at $14.14, $13.51 and $13.71 per share, respectively, to satisfy tax withholding obligations on RSUs granted in 2025, 2024 and 2022. The filing indicates these exempt dispositions were not made under a Rule 10b5-1 trading plan.
AngioDynamics Inc. executive Laura Piccinini, SVP International, reported three exempt dispositions of common stock on July 16, 17 and 20, 2026, totaling 8,228 shares, to satisfy tax withholding obligations on pre-determined vesting of restricted stock units granted on July 16, 2025, July 17, 2024 and July 20, 2022.
AngioDynamics Inc. reports that SVP Quality and Regulatory Warren Nighan Jr. had a total of 3,777 common shares withheld in three exempt dispositions on July 16, 17 and 20, 2026, at prices from $13.51 to $14.14 per share to satisfy tax withholding obligations tied to pre-determined vesting of previously granted restricted stock units. These events were not designated as occurring under a Rule 10b5-1 trading plan.
AngioDynamics Inc. President and CEO James C. Clemmer reported five exempt dispositions of common stock from July 16–20, 2026. In total, 45,711 shares were withheld at per-share prices including $14.1400, $13.5100, and $13.7100 to satisfy tax withholding obligations on previously granted restricted stock units as they vested.